SecSonar.com

Fate Therapeutics, Inc. (FATE)

Fate Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Fate Therapeutics, Inc. (FATE) is a Biotechnology company based in US with a market capitalization of $317M. Revenue declined 51.2% year-over-year and free cash flow was negative at -$112M. This page tracks FATE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 181 employees · IPO Oct 1, 2013

Valuation

Valuation & price

$1.75 · as of May 17, 2026 · -38.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.53

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.84$1.88$0.92Jul 25Dec 25Jun 26Jul 7, 25$1.06Jul 9, 25$1.15Jul 11, 25$1.15Jul 15, 25$1.13Jul 17, 25$1.15Jul 21, 25$1.15Jul 23, 25$1.28Jul 25, 25$1.24Jul 29, 25$1.17Jul 31, 25$1.10Aug 4, 25$1.06Aug 6, 25$1.04Aug 8, 25$0.92Aug 12, 25$0.94Aug 14, 25$1.07Aug 18, 25$1.20Aug 20, 25$1.13Aug 22, 25$1.15Aug 27, 25$1.12Aug 29, 25$1.04Sep 3, 25$1.00Sep 5, 25$1.01Sep 9, 25$0.98Sep 11, 25$1.02Sep 15, 25$0.96Sep 17, 25$0.95Sep 19, 25$0.96Sep 23, 25$0.97Sep 25, 25$0.97Sep 29, 25$1.00Oct 1, 25$1.25Oct 3, 25$1.21Oct 7, 25$1.39Oct 9, 25$1.61Oct 13, 25$1.39Oct 16, 25$1.54Oct 20, 25$1.54Oct 22, 25$1.49Oct 24, 25$1.65Oct 28, 25$1.49Oct 30, 25$1.29Nov 3, 25$1.26Nov 5, 25$1.09Nov 7, 25$1.07Nov 11, 25$1.12Nov 13, 25$0.99Nov 17, 25$0.97Nov 19, 25$1.05Nov 21, 25$1.03Nov 25, 25$1.06Nov 28, 25$1.14Dec 2, 25$1.00Dec 5, 25$1.08Dec 9, 25$1.05Dec 11, 25$1.11Dec 15, 25$1.12Dec 17, 25$1.05Dec 19, 25$1.05Dec 23, 25$0.98Dec 26, 25$1.00Dec 30, 25$0.98Jan 2, 26$0.99Jan 6, 26$1.01Jan 8, 26$1.06Jan 12, 26$1.07Jan 14, 26$1.08Jan 16, 26$1.19Jan 21, 26$1.18Jan 23, 26$1.21Jan 28, 26$1.21Jan 30, 26$1.19Feb 3, 26$1.16Feb 5, 26$1.05Feb 9, 26$1.12Feb 11, 26$1.17Feb 13, 26$1.25Feb 18, 26$1.37Feb 20, 26$1.46Feb 24, 26$1.62Feb 26, 26$1.56Mar 2, 26$1.50Mar 4, 26$1.45Mar 6, 26$1.33Mar 10, 26$1.29Mar 12, 26$1.17Mar 16, 26$1.16Mar 19, 26$1.08Mar 23, 26$1.15Mar 25, 26$1.22Mar 27, 26$1.17Mar 31, 26$1.20Apr 2, 26$1.22Apr 7, 26$1.15Apr 9, 26$1.27Apr 13, 26$1.31Apr 15, 26$1.29Apr 17, 26$1.39Apr 21, 26$1.35Apr 23, 26$1.32Apr 27, 26$1.31Apr 29, 26$1.24May 1, 26$1.53May 5, 26$2.36May 8, 26$2.39May 12, 26$2.25May 14, 26$1.90May 18, 26$1.73May 20, 26$1.84May 22, 26$2.25May 27, 26$2.37May 29, 26$2.84Jun 2, 26$2.57Jun 4, 26$2.21Jun 8, 26$1.91Jun 10, 26$1.87Jun 12, 26$2.06Jun 16, 26$1.90Jun 18, 26$2.09Jun 23, 26$2.16Jun 29, 26$2.42
$0.9252-week range$2.84
Loading valuation history…

Fundamentals

Key fundamentals

$317M

Market cap

-51.2%

Revenue growth (YoY)

-94.1%

Gross margin

-$112M

Free cash flow (USD)

-$125.8M

Net debt

Net cash position

4.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$4.4MFY 2017$4.1MFY 2018$4.7MFY 2019$10.7MFY 2020$31.4MFY 2021$55.8MFY 2022$96.3MFY 2023$63.5MFY 2024$13.6MFY 2025$6.6M
$4.4M$6.6M

Free cash flow by year

2016 → 2025

FY 2016$-30.3MFY 2017$-38.6MFY 2018$-41.0MFY 2019$-90.6MFY 2020$-44.2MFY 2021$-213.6MFY 2022$-283.8MFY 2023$-138.4MFY 2024$-123.6MFY 2025$-112.0M
-$30.3M-$112M

Gross margin by year

2021 → 2025

FY 202189.5%FY 202285.7%FY 2023-147.4%FY 2024100.0%FY 2025-94.1%
89.5%-94.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventStock Option Plan AmendedJun 15, 2026Filing
  • 8-K eventCorporate PresentationJun 4, 2026Filing
  • Insider sellInsider Sell $54KValamehr Bahram · Director, President and CEO · $54.5KMay 21, 2026Filing
  • Insider sellInsider Sell $48KTAHL CINDY · See Remarks · $48.1KMay 21, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing

Questions

Frequently asked questions

What is Fate Therapeutics, Inc.'s market cap?

Fate Therapeutics, Inc. (FATE) has a market capitalization of $317M.

What is FATE's P/E ratio?

A meaningful P/E ratio is not available for FATE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is FATE's price-to-book (P/B) ratio?

FATE trades at 1.53 times book value per share.

Are insiders buying FATE stock?

SEC Form 4 filings show no open-market insider buys at Fate Therapeutics, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

SLN

Silence Therapeutics plc

$320.4M

NAGE

Niagen Bioscience Inc

$311.8M

OABI

OmniAb, Inc.

$323.4M

EVMN

Evommune, Inc.

$324.9M

BCYC

Bicycle Therapeutics plc

$325.5M

XOMAP

XOMA Corporation

$307M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.